newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

  • IGC Pharma filed utility patent applications covering the architectural framework of its Agentic Harmonization Assistant (AHA), an AI-based data harmonization system.
  • AHA is designed to standardize heterogeneous Alzheimer's datasets by automating alignment and validation to address inconsistencies in schema definitions, variable encodings, and data structures.
  • The company has already harmonized 15 Alzheimer's-related datasets for internal development and continues to refine the system architecture.
  • AHA advanced to the semi-final round of a competitive AI research evaluation program earlier this year.
  • IGC plans to present further details on AHA's development roadmap at the upcoming ADPD conference.
  • CEO Ram Mukunda stated that while the primary focus remains the CALMA clinical trial, scalable data harmonization and internal AI capabilities are essential for future research, collaborations, or licensing opportunities.
  • IGC Pharma is a clinical-stage biotechnology company developing IGC-AD1 for Alzheimer's agitation, TGR-63 for amyloid plaques, and other early-stage neurodegeneration programs using AI.
  • The press release includes standard forward-looking statements regarding risks related to product commercialization, regulatory approval, and AI algorithm performance.